For the year ending 2025-12-31, NUVB made $62,902K in revenue. -$205,387K in net income. Net profit margin of -326.52%.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Revenue | 62,902 | 7,873 | ||
| Cost of sales | 856 | - | ||
| Cost of collaboration and license agreements revenue | 8,442 | - | ||
| Cost of revenue | - | 7,078 | ||
| Research and development | 115,106 | 99,119 | ||
| Gross profit, total | - | 795 | ||
| Acquired in-process research and development | 0 | 425,070 | ||
| Selling, general and administrative | 151,562 | 69,233 | ||
| Total costs and expenses | 275,966 | 593,422 | ||
| Loss from operations | -213,064 | -592,627 | ||
| Interest income | 21,430 | 27,062 | ||
| Interest expense | 13,682 | 341 | ||
| Investment advisory fees | 722 | 976 | ||
| Other expense | - | 109 | ||
| Change in fair value of warrants liability | 812 | 936 | ||
| Realized gain (loss) on marketable securities | 5 | -12 | ||
| Net loss on disposal of fixed assets | -33 | - | ||
| Other income (expense) | 2,251 | - | ||
| Total other income, net | 8,437 | 24,688 | ||
| Loss before income taxes | -204,627 | -567,939 | ||
| Provision for income taxes | 0 | - | ||
| Net loss | -204,627 | -567,939 | ||
| Currency translation adjustment | 1,501 | -537 | ||
| Change in unrealized gain (loss) on available-for-sale securities | 741 | -145 | ||
| Comprehensive loss | -205,387 | -567,547 | ||
| Basic EPS | -0.6 | -2.11 | ||
| Diluted EPS | -0.6 | -2.11 | ||
| Basic Average Shares | 341,541 | 268,772 | ||
| Diluted Average Shares | 341,541 | 268,772 | ||
Nuvation Bio Inc. (NUVB)
Nuvation Bio Inc. (NUVB)